Skip to main content
Clinical Trials/NCT04793074
NCT04793074CompletedPhase 4

Transforming Nanoparticle Dressing For Management of Chronic Venous Ulcers

Egyptian Biomedical Research Network1 site in 1 country60 target enrollmentStarted: July 1, 2019Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
60
Locations
1
Primary Endpoint
Time to complete healing (weeks)

Study Overview

Brief Summary

The present randomized controlled study aims to evaluate the role of transforming nanoparticle dressing n management of chronic venous ulcers.

Detailed Description

The present randomized controlled study was conducted at Helwan University Hospitals, Cairo, Egypt. The study protocol was approved by the local ethical committee and all patients gave informed consent before enrollment.

The study included 60 patients with CVU. Patients were diagnosed on the basis of clinical findings and vascular Doppler ultrasonography. Exclusion criteria were associated infection and associated ulcers of other etiologies. Patients randomization was achieved using computer generated numbers and sealed envelope technique. Randomization and patients' allocation to the study interventions was performed by an independent researcher who wasn't aware of the study interventions and outcome.

Upon recruitment, patients were subjected to careful history taking, thorough clinical examination, standard laboratory investigations and vascular ultrasound examination. The recorded parameters included demographic data (age, sex and body mass index), associated morbidities, duration and size of CVU and history of previous interventions.

After randomization, patients in the treatment group (n=30) had transforming nanoparticle dressing while the control group (n=30) received conventional compression dressing. Before applications of both dressings, the wound area was thoroughly cleaned. In the treatment group, the dressing powder was applied as a thin layer to the ulcer surface. Any excess powder surrounding the ulcer area was removed. In both groups, a secondary protective gauze dressing was applied. Patients were follow up at weekly intervals until complete healing occurs.

The primary end-point in the present study is the time to complete healing. The secondary end-point the rate of healing (percent of reduction in ulcer area).

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
30 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Chronic venous ulcers.

Exclusion Criteria

  • Associated infection and associated ulcers of other etiologies.

Outcomes

Primary Outcomes

Time to complete healing (weeks)

Time Frame: 16 weeks

The primary end-point in the present study is the time to complete healing of ulcers

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Egyptian Biomedical Research Network
Sponsor Class
Network
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Transforming Nanoparticle Dressing For... | Clinical Trial